Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7594 for infusion · 1 trial · 2 indications
For oral and inhalation administrations: pre-dose (0 hour) and post-dose at 15, 30 and 45 minutes and 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0, 72.0 and 96.0 hours following the administration of the investigational product AZD7594. For IV administration: pre-dose (0 hour) and post-dose at 5, 10, 15 (end of infusion), 30, 45, 60 and 90 minutes and 2.0, 4.0, 6.0, 8.0, 12.0, 16.0, 48.0, 72.0 and 96.0 hours following the start of the IV infusion of the investigational product AZD7594
| Arm | Type | Description |
|---|---|---|
| Treatment sequence 1 | EXPERIMENTAL | Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation) |
| Treatment sequence 2 | EXPERIMENTAL | Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation) |
| Name | Type | Description |
|---|---|---|
| AZD7594 Solution for infusion (150 μg intravenous formulation) | DRUG | Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV |
| AZD7594 Oral suspension (1200 μg oral formulation) | DRUG | 0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral |
| AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler) | DRUG | Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler) |
| AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) | DRUG | Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI) |
| AZD7594 Pressurized inhalation suspension (400 μg) by pMDI | DRUG | Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male subjects aged 18 - 45 years with suitable veins for cannulation or repeated venipuncture. 3. Have a body mass index (BMI) between 18 and 30 kg/m2, inclusive, and we...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
AZD7594 for infusion is an intravenous formulation of AZD7594, a small molecule being developed by AstraZeneca for asthma. The specific formulation is described as AZD7594 Solution for infusion, a 150 microgram intravenous version. It is an investigational agent in Phase 1 clinical development and has not been approved for any use.
AZD7594 for infusion is being studied for asthma, which falls within the respiratory therapeutic area. The clinical trial involving this formulation also listed chronic obstructive pulmonary disease, or COPD, among the conditions studied. It remains investigational and is not an approved treatment for asthma or any other condition.
AZD7594 for infusion is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor behind the clinical program evaluating this intravenous formulation of the small molecule AZD7594 for respiratory indications including asthma.
AZD7594 for infusion is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The drug is investigational, meaning it has not received regulatory approval and remains in early-stage clinical testing for asthma.
AZD7594 for infusion was evaluated in the Phase 1 trial NCT02648438, titled a study to assess the bioavailability and compare the pharmacokinetics of AZD7594 inhaled via monodose inhaler and multiple-dose dry powder inhalers or pressurized metered-dose inhaler in healthy male subjects. The trial enrolled 30 participants in the United States and is completed.
Yes, AZD7594 for infusion is also known as AZD7594 Solution for infusion, the 150 microgram intravenous formulation. Both names refer to the same intravenous presentation of AZD7594, the small molecule AstraZeneca is developing for asthma. The intravenous formulation is distinct from the inhaled formulations studied in the same Phase 1 program.